Tags

Type your tag names separated by a space and hit enter

FGF-23: the rise of a novel cardiovascular risk marker in CKD.
Nephrol Dial Transplant. 2012 Aug; 27(8):3072-81.ND

Abstract

Elevated plasma levels of the phosphaturic hormone fibroblast growth factor 23 (FGF-23) are a hallmark of chronic kidney disease (CKD)-mineral and bone disorder. FGF-23 allows serum phosphate levels within physiological limits to be maintained in progressive CKD until end-stage renal disease is reached. Despite its seemingly beneficial role in phosphate homeostasis, several prospective studies in dialysis patients and in patients with less advanced CKD associated elevated FGF-23 with poor cardiovascular and renal outcome. Moreover, very recent evidence suggests an adverse prognostic impact of elevated FGF-23 even in subjects without manifest CKD. These epidemiological data are supplemented by laboratory findings that reveal a pathophysiological role of FGF-23 in the pathogenesis of myocardial injury. In aggregate, these clinical and experimental data identify FGF-23 as a promising target of novel therapeutic interventions in CKD and beyond, which should be tested in future clinical trials.

Authors+Show Affiliations

Department of Internal Medicine IV—Nephrology and Hypertension, Saarland University Medical Center, Homburg/Saar, Germany. Gunnar.Heine@uks.euNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22851630

Citation

Heine, Gunnar H., et al. "FGF-23: the Rise of a Novel Cardiovascular Risk Marker in CKD." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 27, no. 8, 2012, pp. 3072-81.
Heine GH, Seiler S, Fliser D. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant. 2012;27(8):3072-81.
Heine, G. H., Seiler, S., & Fliser, D. (2012). FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 27(8), 3072-81. https://doi.org/10.1093/ndt/gfs259
Heine GH, Seiler S, Fliser D. FGF-23: the Rise of a Novel Cardiovascular Risk Marker in CKD. Nephrol Dial Transplant. 2012;27(8):3072-81. PubMed PMID: 22851630.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - FGF-23: the rise of a novel cardiovascular risk marker in CKD. AU - Heine,Gunnar H, AU - Seiler,Sarah, AU - Fliser,Danilo, PY - 2012/8/2/entrez PY - 2012/8/2/pubmed PY - 2013/1/12/medline SP - 3072 EP - 81 JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JO - Nephrol Dial Transplant VL - 27 IS - 8 N2 - Elevated plasma levels of the phosphaturic hormone fibroblast growth factor 23 (FGF-23) are a hallmark of chronic kidney disease (CKD)-mineral and bone disorder. FGF-23 allows serum phosphate levels within physiological limits to be maintained in progressive CKD until end-stage renal disease is reached. Despite its seemingly beneficial role in phosphate homeostasis, several prospective studies in dialysis patients and in patients with less advanced CKD associated elevated FGF-23 with poor cardiovascular and renal outcome. Moreover, very recent evidence suggests an adverse prognostic impact of elevated FGF-23 even in subjects without manifest CKD. These epidemiological data are supplemented by laboratory findings that reveal a pathophysiological role of FGF-23 in the pathogenesis of myocardial injury. In aggregate, these clinical and experimental data identify FGF-23 as a promising target of novel therapeutic interventions in CKD and beyond, which should be tested in future clinical trials. SN - 1460-2385 UR - https://www.unboundmedicine.com/medline/citation/22851630/FGF_23:_the_rise_of_a_novel_cardiovascular_risk_marker_in_CKD_ L2 - https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfs259 DB - PRIME DP - Unbound Medicine ER -